News
Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile marred the results.
“Friends of Cancer Research has long been a catalyst for forward-thinking collaboration in oncology, and we are grateful they have trusted MMS to support this vital initiative,” said Uma Sharma, PhD, ...
KLN-1010 is the first anti-BCMA in vivo CAR-T program studied in a multi-center clinical trial KLN-1010 is administered directly to patients without apheresis, ex vivo manufacturing or lymphodepletion ...
NEEDHAM, Mass. and KYIV, Ukraine (August 19, 2025) – Trialt, a global clinical research organization (CRO) specializing in biostatistics, statistical programming, data management, and medical writing, ...
The small molecule, vatiquinone, had already flunked a Phase III trial, but the company pushed ahead with an approval bid anyway. The FDA has rejected PTC Therapeutics’ vatiquinone, the company’s ...
The FDA has postponed its decision date for Regenxbio’s Hunter syndrome gene therapy to review additional longer-term clinical data for the asset.
In Phase III studies, Tonmya showed significantly superior analgesic effects in patients with fibromyalgia versus placebo. The sublingual pill also led to better clinical outcomes.
SEOUL, South Korea-- (BUSINESS WIRE)--On August 6, 2025, VASTHERA Co., Ltd. announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to ...
While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured investors it has the manufacturing capacity to roll out oral semaglutide ...
Calgary, Alberta-- (Newsfile Corp. - August 19, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy ...
Adaptive and Genentech first partnered in 2018 to advance T cell receptor-based therapies for cancer. Adaptive Biotechnologies lost a powerhouse partner after Roche subsidiary Genentech walked away ...
Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that further data on efficacy, safety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results